We use cookies on our website. Carry on browsing if you’re happy with this or find out more

About us


We are a therapeutic antibody company

Based in Cambridge, UK, we’re working with partners to provide novel solutions in drug and vaccine development. Using our unique technology, we rapidly develop broad diversity, high quality human antibodies against challenging targets.

Working with partners since 2010

With investment totalling $220m, we are using our antibody platforms to help our partners to realise new opportunities in therapeutic and vaccine development.

Our history

From the Wellcome Trust Sanger Institute’s first spin-out to a leading therapeutic antibody company.

Learn more

Our vision

Our vision is to be a global biopharmaceutical company, driving the development of therapeutic human antibodies.

Learn more

Our partnerships

We work in partnerships, enhancing each other’s complementary skills to rapidly discover and test validated lead prospects.

Learn more

World leading partners

  • Bill & Melinda Gates Foundation
  • Heptares Therapeutics
  • Novo Nordisk
  • Wellcome Trust
View our partnerships

Our intellectual power

have a Bachelor’s degree
have a PhD
countries represented

Led by a team with world-class antibody development experience, we recruit key people to all parts of Kymab with a proven record in drug development, antibody therapeutics, disease studies, business development and financial control.

Kymab Group Ltd: The Bennet Building (B930), Babraham Research Campus, Cambridge, United Kingdom, CB22 3AT. Registered in England. Company registration number 10414057.

Kymab has one of the most comprehensive transgenic technologies.

Trevor Mundel, Global Health President, Bill & Melinda Gates Foundation: Press Release, 16 May 2014